Are There Ongoing Trials for Folinic Acid in Autism?
Yes, there are ongoing clinical trials evaluating folinic acid (leucovorin) for autism spectrum disorder, with multiple recent studies published between 2021-2025 demonstrating active research interest in this intervention.
Current Research Landscape
The evidence base for folinic acid in ASD has expanded significantly in recent years, with several completed randomized controlled trials and open-label studies published from 2021 through 2025 1, 2, 3, 4. This recent surge in publications indicates robust ongoing research activity, though the specific status of currently enrolling trials is not detailed in the provided evidence.
Recent Completed Studies (2021-2025)
The most recent high-quality evidence includes:
2025: A randomized trial in Chinese children (n=80) examining high-dose folinic acid (2 mg/kg/day, max 50 mg/day) over 12 weeks, which found improvements in social reciprocity and demonstrated that efficacy correlates with folate metabolism gene polymorphisms (MTHFR C677T, MTHFR A1298C, MTR A2756G, MTRR A66G) 1
2024: A double-blind, placebo-controlled RCT (n=80) showing significant improvements in CARS scores (3.6 ± 0.8 vs 2.4 ± 0.7, p < 0.001) and behavioral problems, with more pronounced benefits in children with high-titer folate receptor autoantibodies 2
2025: An open-label within-subjects study (n=10) demonstrating safety and feasibility with medium-large effect sizes on autism composite scores, though not statistically significant due to small sample size 3
2021: A double-blind RCT (n=55) as adjunctive therapy to risperidone showing significant improvements in inappropriate speech, stereotypic behavior, and hyperactivity 4
Key Research Findings
Biomarker Development
Recent research has identified folate receptor autoantibodies as potential biomarkers for treatment response. High-titer autoantibodies are present in 71-82% of children with ASD 2, 5, and these children show more pronounced improvements with folinic acid treatment 2.
Genetic Predictors
The 2025 Chinese study broke new ground by demonstrating that folate metabolism gene polymorphisms predict treatment response, with children carrying MTHFR A1298C or MTRR A66G mutations showing greater improvements than wild-type 1.
Safety Profile
All recent trials consistently report no significant adverse effects with folinic acid at doses of 2 mg/kg/day (maximum 50 mg/day) 1, 2, 3, 4.
Important Clinical Context
Current Guideline Position
The 2014 AACAP practice parameter does not specifically address folinic acid for ASD 6. The American Academy of Pediatrics currently does not recommend leucovorin use in children with ASD 5, though this position predates the most recent high-quality RCT evidence from 2024-2025.
Emerging Clinical Interest
Despite lack of formal guideline endorsement, there is increasing clinical demand for leucovorin prescriptions, driven by social media attention and recent political advocacy 5, 7. This creates a gap between emerging evidence and established recommendations.
Critical Caveats
The evidence remains preliminary despite recent positive trials:
- Sample sizes are relatively small (10-80 participants)
- Most studies are from single centers or specific populations
- Long-term safety and efficacy data beyond 24 weeks are lacking
- The biological mechanism linking cerebral folate deficiency to ASD symptoms remains incompletely understood 5
Biomarker testing is not standardized: While folate receptor autoantibodies and genetic polymorphisms show promise as predictors of response, these tests are not widely available in routine clinical practice.
The trajectory of research from 2021-2025 suggests continued active investigation, with increasing methodological rigor (progression from open-label to double-blind RCTs) and focus on precision medicine approaches using biomarkers and genetic testing to identify treatment responders.